İbrahim Celalettin HAZNEDAROĞLU, Neslihan DİKMENOĞLU FALKMARKEN, Salih AKSU, Rafiye ÇİFTÇİLER

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study

Background/aim: Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a prohemostatic agent affecting erythrocytes.The hemostatic action of ABS depends upon fibrinogen gamma chain, prothrombin, and red blood cells. The aim of this study was toassess the effects of ABS on erythrocyte aggregation via hemorheological analyses.Materials and methods: To measure erythrocyte aggregation, blood samples were obtained from healthy, nonsmoker volunteers whohad not taken any medication in the previous 10 days. One mL of blood was placed into the laser-assisted optical rotational cell analyzer(LORCA), into the chamber formed by the gap between two concentric glass cylinders. The solution prepared with ABS and saline wasadded to blood in incremental amounts of 10 µL, 20 µL, 30 µL, 40 µL, 50 µL, 60 µL, 70 µL, and 100 µL. Erythrocyte aggregation wasdetermined by laser-assisted optical rotational cell analyzer at 37 °C.Results: AMP was found to be 17.7 ± 2.1 au in the blood without ABS, whereas it was lower in the blood with ABS. AMP was 16.0 ±3.3 in the ABS-added blood group. RBC aggregates did not form faster when cells contacted ABS. The t t½ value was 4.6 ± 2.6 in theABS-added blood group and 1.9 ± 0.20 in the control group. Aggregation was faster in the control group (P = 0.03). AI, which is acombination of AMP and t½, was lowered in the ABS group (48.7 ± 12.3) compared to the control group (65.8 ± 1.6) (P = 0.02). It wasnotable that the γIsc max (sec-1) value of the control was higher (200 ± 106) than the ABS-added blood group (141 ± 51.0).Conclusion: ABS has antierythroid aggregation effect. ABS inhibits pathological aggregation of red blood cells. Antithrombotic clinicaleffects of ABS may be ascribed to the antierythroid aggregan actions of the drug.

PDF

___

1. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010; 15: 329-36.
2. Goker H, Haznedaroglu I, Ercetin S, Kirazli S, Akman U, Ozturk Y, Firat HC. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper®. Journal of International Medical Research. 2008; 36: 163-170.
3. Eğin Y, Köse YAK, Haznedaroğlu İC, Akar N. Anti-thrombin activity of Ankaferd Hemostat in relation to the platelet functions. Turkiye Klinikleri Journal of Hematology Special Topics. 2015; 8: 106-112.
4. Woodburn K, Rumley A, Love J, Murray G, Lowe G. Influence of graft material on blood rheology and plasma biochemistry following insertion of an infrainguinal bypass graft. British Journal of Surgery. 1998; 85: 351-354.
5. Marossy A, Švorc P, Kron I, Grešová S. Hemorheology and circulation. Clinical Hemorheology and Microcirculation. 2009; 42: 239-258.
6. Arıhan O, Seringeç NB, Gürel EI, Dikmenoğlu NH. Effects of oral acrylamide intake on blood viscosity parameters in rats. Clinical Hemorheology and Microcirculation. 2011; 47: 45-52.
7. Hardeman M, Dobbe J, Ince C. The laser‐assisted optical rotational cell analyzer (LORCA) as red blood cell aggregometer. Clinical hemorheology and microcirculation. 2001; 25: 1-11.
8. Zijlstra W. Syllectometry, a new method for studying rouleaux formation of red blood cells. Acta physiologica et pharmacologica neerlandica.1958; 7: 153-154.
9. Brinkman R, Zijlstra W, Jansonius N. Quantitative evaluation of the rate of rouleaux formation of erythrocytes by measuring light reflection (“ syllectometry”). Proceedings of the Koninklijke Nederlandse Akademie van Wetenschappen Series C Biological and medical sciences. 1963; 66: 236-248.
10. Hardeman M, Goedhart P, Dobbe J, Lettinga K. Laser-assisted optical rotational cell analyser (LORCA); I. a new instrument for measurement of various structural hemorheological parameters. Clinical Hemorheology and Microcirculation. 1994; 14: 605-618.
11. Baskurt O, Boynard M, Giles Cokelet BM, Forconi R, Liao F, Hardeman M, Jung F, Meiselman H. New guidelines for hemorheological laboratory techniques. Clin Hemorheol Microcirc 2009; 42: 75-97.
12. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, Bilgili H, Goker H, Kosar A, Aktas A, Captug O, Kurt M, Ozdemir O et al. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper. Clinical and Applied Thrombosis/Hemostasis 2010; 16: 446-453.
13. Demiralp DÖ, Haznedaroğlu İC, Akar N. Functional proteomic analysis of Ankaferd Blood Stopper. Turkish Journal of Hematology 2010; 27: 70-77.
14. Akpinar MB, Atalay A, Atalay H, Dogan OF. Ankaferd blood stopper decreases postoperative bleeding and number of transfusions in patients treated with clopidogrel: a double-blind, placebo-controlled, randomized clinical trial. The Heart Surgery Forum 2015; 18: 118-123.
15. Atalay H, Atalay A, Dogan OF. Local use of ankaferd blood clotter in emergent beating heart coronary artery bypass grafting. The open cardiovascular medicine journal. 2015; 9: 18.
16. Ergenoglu M, Yerebakan H, Kucukaksu D. A new practical alternative for the control of sternal bleeding during cardiac surgery: Ankaferd Blood Stopper. Heart Surgery Forum 2010; 13: 379-380.
17. Beyazit Y, Sayilir A, Suvak B, Torun S, Haznedaroglu I. Molecular basis of Ankaferd-induced hemostasis in the management of sternal bleeding. Heart Surgery Forum 2012; 15: 305.
18. Koluman A, Akar N, Malkan UY, Haznedaroglu IC. Qualitative/chemical analyses of Ankaferd hemostat and its antioxidant content in synthetic gastric fluids. BioMed Research International 2016; 2016.
19. Akar N, Ardçoglu Y, Öktem Z, Erduran N, Haznedaroglu IC. High iron content of Ankaferd hemostat as a clue for its hemostatic action of red blood cell origin. Blood Coagulation and Fibrinolysis. 2015; 26: 233-234.
20. Franchini M, Targher G, Montagnana M, Lippi G. Iron and thrombosis. Annals of hematology 2008; 87: 167-173.